Management of Acute Asthma or COPD Exacerbations

Rationale for Prioritizing Nebulized Bronchodilators

The European Respiratory Society and British Thoracic Society recommend that for acute severe asthma or COPD exacerbations, nebulized β-agonists (albuterol) combined with ipratropium bromide should be given immediately upon presentation, as they provide immediate relief of bronchospasm 1, 2, 3
For adults with severe symptoms, treatment consists of oxygen plus oral steroids plus nebulized β-agonist, repeated 4-6 hourly, according to the European Respiratory Society guidelines 1, 2, 3
If response to β-agonist alone is poor, the European Respiratory Society suggests adding ipratropium bromide 500 μg to the β-agonist and considering hospital admission 1, 2, 3
The American Thoracic Society recommends that for moderate to severe exacerbations, combination therapy with both β-agonist and anticholinergic (as in Combivent) should be administered together 4

The European Respiratory Society and British Thoracic Society establish a clear stepwise approach for chronic management: first optimize hand-held inhaler therapy, then increase doses via hand-held inhaler if necessary, and only consider nebulizer therapy after optimizing inhaled therapy 5, 6, 7
Oral methylxanthines, such as doxofylline, are considered as adjunctive therapy after optimizing inhaled bronchodilators, according to the European Respiratory Society guidelines 8

For acute presentations, the American College of Chest Physicians recommends immediately administering Combivent nebulization, adding oxygen and oral corticosteroids concurrently, and repeating nebulization every 4-6 hours or more frequently if needed 1, 2, 3
For chronic management, the European Respiratory Society suggests optimizing hand-held inhaler therapy first, considering adding oral doxofylline as adjunctive maintenance therapy if inhaled therapy alone is insufficient, and reserving nebulizer therapy for patients who cannot use hand-held devices or require high-dose therapy despite optimization 5, 6, 7

The European Respiratory Society warns against substituting oral doxofylline for nebulized bronchodilators in acute exacerbations, as the onset of action and route of delivery make nebulized therapy superior for immediate bronchodilation 1, 2, 3
The British Thoracic Society advises against starting doxofylline without first optimizing inhaled therapy, as approximately 50% of patients can achieve adequate control with properly dosed hand-held inhalers 5, 6, 7
The American Thoracic Society recommends monitoring for neurological side effects when initiating doxofylline, particularly in elderly patients, although the strength of evidence for this recommendation is not provided 4

For acute exacerbations of COPD and asthma, the American Thoracic Society recommends administering one 3 mL vial of Duoneb (containing ipratropium 0.5 mg and albuterol 2.5 mg) every 4-6 hours, with more frequent dosing (every 1-4 hours) permitted during severe exacerbations until clinical improvement occurs 9, 10
In severe cases of COPD and asthma, the guideline suggests increasing the frequency of Duoneb administration to every 1-4 hours until improvement, then spacing back to every 4-6 hours 10
The maximum frequency of Duoneb administration can be hourly in severe exacerbations under medical supervision, as recommended by the European Respiratory Society 10
Regular nebulized bronchodilator treatment should only be used after formal evaluation by a specialist and failure of hand-held inhalers at appropriate doses, according to the British Thoracic Society 9, 10

For acute severe asthma, the guideline recommends starting with nebulized β-agonist (albuterol 2.5-5 mg) plus oxygen plus oral steroids, and if inadequate response, adding ipratropium 500 μg (equivalent to one Duoneb vial) to the β-agonist and repeating every 4-6 hours 10
In severe cases of COPD exacerbations, the guideline suggests considering combination therapy every 4-6 hours and hospital admission if not improving, as recommended by the Global Initiative for Chronic Obstructive Lung Disease 10

The nebulization technique is crucial, and the guideline recommends continuing nebulization until approximately one minute after "spluttering" occurs (typically 5-10 minutes), not until complete dryness, as suggested by the American College of Chest Physicians 9
When administering ipratropium to patients with glaucoma, the guideline advises using a mouthpiece rather than a mask to avoid ocular exposure, according to the National Institute for Health and Care Excellence 10
The guideline warns against prescribing Duoneb for chronic maintenance without specialist evaluation and recommends using 24% Venturi mask instead of nebulized therapy with oxygen in COPD patients between treatments, as recommended by the European Respiratory Society 10